Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "CRDMO"

33 News Found

WuXi XDC and AbTis sign MoU for manufacturing of antibody drug conjugates
Biotech | July 10, 2022

WuXi XDC and AbTis sign MoU for manufacturing of antibody drug conjugates

AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing

WuXi STA opens Oligonucleotide and Peptide manufacturing facility
News | July 08, 2022

WuXi STA opens Oligonucleotide and Peptide manufacturing facility

Site Enhances New Modality CRDMO Platform Capacity for Customers

CPC Scientific announces new California peptide API manufacturing facility
News | June 24, 2022

CPC Scientific announces new California peptide API manufacturing facility

The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity

Latest Stories

Roche presents new Alzheimer’s research at AAIC 2025

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development

Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine with near-zero GWP

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging